# US 2023/0405133 A1 · Purified multivalent protein-hyaluronic acid polymer conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405133 A1
- Document ID: US20230405133A1
- Status: Published application
- Kind: A1
- Application number: 18/300,831
- Filed: 2023-04-14
- Published: 2023-12-21
- Earliest claimed: 2022-04-15
- Assignees: Valitor, Inc.
- Applicants: Valitor, Inc.
- Inventors: Wesley M. JACKSON; Amy A. TWITE; Adam BARNEBEY; Livia Wilz BRIER; Jesse M. MCFARLAND
- Web page: https://patentgrep.com/patent/US20230405133A1

## CPC

- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- C07K 14/52: Cytokines; Lymphokines; Interferons
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/245: {IL-1}
- C07K 16/246: {IL-2}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- C08G 65/48: Polymers modified by chemical after-treatment
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

The present invention relates to purified hyaluronic acid conjugates comprising biologically active peptides. The invention further relates to pharmaceutical compositions of the conjugates, and methods of preparing them.

## Claims

### Claim 1

A conjugate that is a random polymer of Formula III:
(X—Y—Z1)n—(Z2)p—(Z3)q (III),
having a molecular weight of from about 0.1 MDa to about 3 MDa;
wherein
each X is independently a peptide having a molecular weight of from about 5 kDa to about 200 kDa;
each Y is an organic linker;
each X—Y-Z1 moiety has the structure:
each Z2 has the structure:
each Z3 independently has the structure:
each R1 and R2 is independently C1-C6 alkyl, —(C1-C6 alkyl)-NR3R4, or C5-C8 cycloalkyl;
each R3 and R4 is independently H or C1-C6 alkyl;
each Z3a is independently OH or Y′;
each Y′ is an unreacted organic linker;
subscript n is an integer of from 1 to 1500 and less than about 15% of the sum of subscripts n, p, and q;
subscript p is an integer of from 0 to 1000 and less than about 10% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 100 to 10000.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the conjugate has the structure of Formula IIIa:
(X1—X2—Y—Z1)n(Z2)p—(Z3)q (IIIa),
wherein
each X1 comprises a peptide having Formula (I):
FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 (I),
CDR1, CDR2, and CDR3 are each independently complementarity-determining regions;
FR1 has an amino acid sequence comprising
(SEQ ID NO: 1)
X10VQLX11EX12GGGX13X14QX15GX16SLRLSCX17X18SG,
wherein
X10 is Q, E, or D,
X11 is V, Q, A, or E,
X12 is S or T,
X13 is L, S, or V,
X14 is V or A,
X15 is P, A, or T,
X16 is G, D, or R,
X17 is A, V, T, or E, and
X18 is A or V;
FR2 has an amino acid sequence comprising
(SEQ ID NO: 2)
X20X21WX22RQX23PGKX24X25EX26VX27X28I,
wherein
X20 is M, I, V, or L,
X21 is G, S, or A,
X22 is F, Y, or V,
X23 is A, V, P, or T,
X24 is E, G, A, or Q,
X25 is R or L,
X26 is F, G, W, or L,
X27 is A, G, or S, and
X28 is A, S, or G;
FR3 has an amino acid sequence comprising
(SEQ ID NO: 3)
YX30DSVKGRFTISX31DX32X33KX34X35VX36LQMX37X38LRX39ªEDTAX39b
YYCAA,
wherein
X30 is A, G, S, or T,
X31 is R or Q,
X32 is N, S, or D,
X33 is S, A, or D,
X34 is N or K,
X35 is T or M,
X36 is Y, D, or S,
X37 is N or D,
X38 is S or N,
X39a is P or A, and
X39b is V, M, L, or I;
and
FR4 has an amino acid sequence comprising
(SEQ ID NO: 4)
YWGX40GTX41VTVSS,
wherein
X40 is Q or K, and
X41 is L or Q; and
each X2 is a peptide linker that comprises an alpha-helix.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein X27 is A.

### Claim 4 (depends on 2, 3)

The conjugate of any one of claims 2 to 3, wherein X39a is P.

### Claim 5 (depends on 2, 3, 4)

The conjugate of any one of claims 2 to 4, wherein
FR1 has an amino acid sequence comprising
(SEQ ID NO: 5)
QVQLVESGGGLVQPGGSLRLSCAASG.

### Claim 6 (depends on 2, 3, 4, 5)

The conjugate of any one of claims 2 to 5, wherein
FR2 has an amino acid sequence comprising
(SEQ ID NO: 6)
MGWFRQAPGKEREFVAAI.

### Claim 7 (depends on 2, 3, 4, 5, 6)

The conjugate of any one of claims 2 to 6, wherein
FR3 has an amino acid sequence comprising
(SEQ ID NO: 7)
YADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAA.

### Claim 8 (depends on 2, 3, 4, 5, 6, 7)

The conjugate of any one of claims 2 to 7, wherein FR4 has an amino acid sequence comprising YWGQGTLVTVSS (SEQ ID NO: 8).

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The conjugate of any one of claims 2 to 8, wherein CDR1, CDR2, and CDR3 are each complementarity-determining regions from an antibody or a cytokine.

### Claim 10 (depends on 9)

The conjugate of claim 9, wherein the antibody is a monoclonal IgG, an IgG fragment, single chain scFv, single-domain heavy-chain VHH, adnectin, affibody, anticalin, DARPin, or an engineered Kunitz-type inhibitor.

### Claim 11 (depends on 9, 10)

The conjugate of claim 9 or 10, wherein the complementarity-determining regions are each specific to vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α), programmed cell death protein 1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), cluster of differentiation 40 (CD40), cluster of differentiation 134 (CD134), cluster of differentiation 137 (CD137), glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), V-domain immunoglobulin suppressor of T-cell activation (VISTA), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), lymphocyte activating 3 (LAG3), interleukin-1-beta (IL-1R), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), or interleukin-15 (IL-15).

### Claim 12 (depends on 9, 10)

The conjugate of claim 9 or 10, wherein the complementarity-determining regions are each specific to vascular endothelial growth factor (VEGF).

### Claim 13 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The conjugate of any one of claims 2 to 12, wherein the peptide consists of Formula I.

### Claim 14 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The conjugate of any one of claims 2 to 13, having one or more of the following:
(a) a CDR1 of 7 amino acids in length;
(b) a CDR2 of 7 or 8 amino acids in length; and/or
(c) a CDR3 of 9 to 16 amino acids in length.

### Claim 15 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The peptide of any one of claims 2 to 14, wherein:
(a) CDR1 has an amino acid sequence comprising FAYSTYS (SEQ ID NO: 9),
CDR2 has an amino acid sequence comprising NSGTFRLW (SEQ ID NO: 10), and
CDR3 has an amino acid sequence comprising RAWSPYSSTVDAGDFR (SEQ ID NO: 11); or
(b) CDR1 has an amino acid sequence comprising RRFSIEA (SEQ ID NO: 12),
CDR2 has an amino acid sequence comprising DSGGSTD (SEQ ID NO: 13), and
CDR3 has an amino acid sequence comprising IGGSWYGRGLD (SEQ ID NO: 14); or
(c) CDR1 has an amino acid sequence comprising GTFSSII (SEQ ID NO: 15),
CDR2 has an amino acid sequence comprising SWSGGTTV (SEQ ID NO: 16), and
CDR3 has an amino acid sequence comprising RPYQKYNWASASYNV (SEQ ID NO: 17); or
(d) CDR1 has an amino acid sequence comprising GGSDAGT (SEQ ID NO: 18),
CDR2 has an amino acid sequence comprising SWAGTAWR (SEQ ID NO: 19), and
CDR3 has an amino acid sequence comprising LGSYEMDHH (SEQ ID NO: 20).

### Claim 16 (depends on 2)

The conjugate of claim 2, wherein each X1 is a peptide having an amino acid sequence comprising any one of SEQ ID NOS: 51-58, 61-73, 81-85, 91-95, 101-106, and 111-118.

### Claim 17 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The conjugate of any one of claims 2 to 16, wherein
each X2 is a peptide linker having an amino acid sequence comprising:
(SEQ ID NO: 21)
AEAAAKEAAAKEAAAKAGC,
(SEQ ID NO: 22)
AEEEKRKAEEEKRKAEEEAGC,
(SEQ ID NO: 23)
AEEEKRKAEEEKRKAEEEKRKAEEEAGC,
(SEQ ID NO: 24)
AEEEEKKKKEEEEKKKKAGC,
(SEQ ID NO: 25)
AEAAAKEAAAKAGC,
(SEQ ID NO: 26)
PSRLEEELRRRLTEGC,
or
(SEQ ID NO: 27)
AEEEEKKKQQEEEAERLRRIQEEMEKERKRREEDEERRRKEEEERRM
KLEMEAKRKQEEEERKKREDDEKRKKKAGC.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The conjugate of any one of claims 1 to 17, wherein the organic linker has the structure:
and
subscript m is an integer of from 1 to 300.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The conjugate of any one of claims 1 to 18, wherein the organic linker has the structure:

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The conjugate of any one of claims 1 to 19, wherein the random polymer of Formula III has a molecular weight of from about 0.4 MDa to about 2 MDa.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The conjugate of any one of claims 1 to 20, wherein the random polymer of Formula III has a molecular weight of from about 0.7 MDa to about 1.5 MDa.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The conjugate of any one of claims 1 to 21, wherein the random polymer of Formula III has a molecular weight of about 0.8 MDa.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The conjugate of any one of claims 1 to 22, wherein each R1 and R2 is independently C1-C3 alkyl or —(C1-C3 alkyl)-NR3R4.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The conjugate of any one of claims 1 to 23, wherein each R3 and R4 is independently C1-C3 alkyl.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The conjugate of any one of claims 1 to 24, wherein
subscript n is an integer of from 1 to 1500 and less than about 15% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 1000 and less than about 10% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 100 to 10000.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The conjugate of any one of claims 1 to 25, wherein
subscript n is an integer of from 1 to 1000 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 800 and less than about 8% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 100 to 10000.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The conjugate of any one of claims 1 to 26, wherein
subscript n is an integer of from 10 to 450 and less than about 15% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 300 and less than about 10% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The conjugate of any one of claims 1 to 27, wherein
subscript n is an integer of from 10 to 300 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 240 and less than about 8% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugate of any one of claims 1 to 28, wherein
subscript n is an integer of from 10 to 300 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 60 and less than about 2% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The conjugate of any one of claims 1 to 29, wherein
subscript n is an integer of from 10 to 300 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 30 and less than about 1% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The conjugate of any one of claims 1 to 30, wherein
subscript n is an integer of from 10 to 300 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 15 and less than about 0.5% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000.

### Claim 32

A conjugate that is a random polymer of Formula IIIa:
(X1—X2—Y—Z1)n—(Z2)p—(Z3)q (IIIa),
having a molecular weight of about 0.8 MDa;
wherein
each X1 is a peptide having an amino acid sequence comprising SEQ ID NO: 55;
each X2 is a peptide linker having an amino acid sequence comprising
(SEQ ID NO: 21)
AEAAAKEAAAKEAAAKAGC;
each Y is an organic linker having the structure:
each X1—X2—Y—Z1 moiety has the structure:
each Z2 has the structure:
each Z3 independently has the structure:
each Z3a is independently OH or Y′;
each Y′ has the structure:
each R1 and R2 is ethyl or —(CH2)3—NMe2;
subscript n is an integer of from 10 to 300 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 15 and less than about 0.5% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000.

### Claim 33

A conjugate that is a random polymer of Formula IIIa:
(X1—X2—Y—Z1)n—(Z2)p—(Z3)q (IIIa),
having a molecular weight of about 0.8 MDa;
wherein
each X1 is a peptide having an anti-VEGF amino acid sequence comprising SEQ ID NO: 67;
each X2 is a peptide linker having an amino acid sequence comprising
(SEQ ID NO: 21)
AEAAAKEAAAKEAAAKAGC;
each Y is an organic linker having the structure:
each X1—X2—Y—Z1 moiety has the structure:
each Z2 has the structure:
each Z3 independently has the structure:
each Z3a is independently OH or Y′;
each Y′ has the structure:
each R1 and R2 is ethyl or —(CH2)3—NMe2;
subscript n is an integer of from 10 to 300 and less than about 10% of the sum of subscripts n, p, and q;
subscript p is an integer of from 1 to 15 and less than about 0.5% of the sum of subscripts n, p, and q; and
subscript q is an integer of from 1000 to 3000.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A pharmaceutical composition comprising a conjugate of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject a conjugate of any one of claims 1 to 33.

### Claim 36 (depends on 35)

The method of claim 35, comprising intravitreally administering the conjugate.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, comprising administering the conjugate every month, every two months, or every three months.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35 to 37, wherein the vitreous half-life of the conjugate is at least 5-fold greater than the half-life of the unconjugated peptide.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35 to 38, wherein the ocular disorder is uveitis, macular degeneration, choroidal neovascularization, retinal neovascularization, proliferative vitreoretinopathy, glaucoma, or ocular inflammation.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of treating a disease or disorder in an articular joint in a subject in need thereof, comprising administering to the subject a conjugate of any one of claims 1 to 33.

### Claim 41 (depends on 40)

The method of claim 40, comprising intraarticularly administering the conjugate.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, comprising administering the conjugate every month, every two months, or every three months.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40 to 42, wherein the intraarticular half-life of the conjugate is at least 5-fold greater than the half-life of the unconjugated peptide.

### Claim 44 (depends on 40, 41, 42, 43)

The method of any one of claims 40 to 43, wherein the disease or disorder is rheumatoid arthritis, wear-related osteoarthritis, age-related osteoarthritis, post-traumatic osteoarthritis, psoriatic arthritis, and aseptic implant loosening, joint effusion, ankylosing spondylitis, bursitis, gout, reactive arthritis, synovitis, or avascular necrosis.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of preparing a conjugate of any one of claims 1 to 33, the method comprising:
(a) forming a first reaction mixture comprising a hyaluronic acid polymer having a molecular weight of from about 0.1 MDa to about 3 MDa, from about 0.1 to about 2 equivalents coupling agent per hyaluronic acid monomer, and an organic linker agent of formula H2N—RY,
wherein
RY is
subscript m is an integer of from 1 to 300;
thereby forming an intermediate polymer having a plurality of monomers of Formula IV:
and
(b) forming a second reaction mixture comprising the intermediate polymer and a peptide having a molecular weight of from about 5 kDa to about 200 kDa, wherein the peptide comprises one or more —SH;
thereby preparing the conjugate.

### Claim 46 (depends on 45)

The method of claim 45, wherein the hyaluronic acid polymer has a molecular weight of from about 0.4 MDa to about 2 MDa.

### Claim 47 (depends on 45)

The method of claim 45, wherein the hyaluronic acid polymer has a molecular weight of from about 0.7 MDa to about 1.5 MDa.

### Claim 48 (depends on 45)

The method of claim 45, wherein the hyaluronic acid polymer has a molecular weight of about 0.8 MDa.

### Claim 49 (depends on 45, 46, 47, 48)

The method of any one of claims 45 to 48, wherein the first reaction mixture comprises from about 0.2 to about 1.5 equivalents coupling agent per hyaluronic acid monomer.

### Claim 50 (depends on 45, 46, 47, 48)

The method of any one of claims 45 to 48, wherein the first reaction mixture comprises from about 0.2 to about 1 equivalent coupling agent per hyaluronic acid monomer.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

The method of any one of claims 45 to 50, wherein the coupling agent comprises a carbodiimide.

### Claim 52 (depends on 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 45 to 51, wherein the coupling agent is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 1,3-diisopropylcarbodiimide, or dicyclohexyl carbodiimide, or a salt thereof.

### Claim 53 (depends on 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 45 to 52, wherein RY is

### Claim 54 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 45 to 53, wherein the first reaction mixture comprises from about 0.2 to about 6 equivalents of the organic linker agent per hyaluronic acid monomer.

### Claim 55 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 45 to 54, wherein the first reaction mixture comprises a catalyst.

### Claim 56 (depends on 55)

The method of claim 55, wherein the catalyst is ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma), hydroxybenzotriazole, N-hydroxysuccinimide (NHS), N-hydroxysulfosuccinimide (sulfo-NHS), or 1-hydroxy-7-azabenzotriazole, or a salt thereof.

### Claim 57 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 45 to 56, wherein the second reaction mixture comprises from about 0.5 to about 1.5 equivalents peptide per organic linker.
